中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (6): 1555-1564.doi: 10.4103/NRR.NRR-D-24-00098

• 综述:退行性病与再生 • 上一篇    下一篇

运动激素鸢尾素对阿尔茨海默病的治疗潜力

  

  • 出版日期:2025-06-15 发布日期:2024-11-10

Therapeutic potential of exercise-hormone irisin in Alzheimer’s disease

Eunhee Kim1, 2, Rudolph E. Tanzi1, 2, Se Hoon Choi1, 2, *   

  1. 1 Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA;  2 McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA
  • Online:2025-06-15 Published:2024-11-10
  • Contact: Se Hoon Choi, PhD, Choi.SeHoon@mgh.harvard.edu.
  • Supported by:
    This work was supported by Cure Alzheimer’s Fund (to RET and SHC), JPB Foundation (to RET), and R56AG072054 (to SHC).

摘要: https://orcid.org/0000-0002-7905-4380 (Se Hoon Choi)

Abstract: Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type III domain-containing protein 5 (FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective functions against Alzheimer’s disease, the most common form of dementia in the elderly, by improving cognitive function and reducing amyloid-β and tau pathologies as well as neuroinflammation in cell culture or animal models of Alzheimer’s disease. Although current and ongoing studies on irisin/FNDC5 show promising results, further mechanistic studies are required to clarify its potential as a meaningful therapeutic target for alleviating Alzheimer’s disease. We recently found that irisin treatment reduces amyloid-β pathology by increasing the activity/levels of amyloidβ-degrading enzyme neprilysin secreted from astrocytes. Herein, we present an overview of irisin/FNDC5’s protective roles and mechanisms against Alzheimer’s disease.

Key words: Alzheimer’s disease, exercise, fibronectin type III domain-containing protein 5 (FNDC5), irisin